TECHWIRE 30
(CIX: WRAL30)  1,123.60  down arrow-1.21  (-0.11 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: Apple)  113.29  up arrow+0.37  (0.33 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NY: QUINTILES)  75.24  up arrow+1.04  (1.4 %)  Updated: 06:40 PM EDT, Aug 28 2015
(OP: BASF SE)  80.48  down arrow-0.5  (-0.62 %)  Updated: 05:20 PM EDT, Aug 28 2015
(NQ: BioCryst)  11.42  up arrow+0.21  (1.87 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: BioDelivery)  6.87  up arrow+0.23  (3.46 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: CEMP)  35.80  up arrow+1.4  (4.07 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: Cisco)  26.00  down arrow-0.17  (-0.65 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: Cree)  26.99  up arrow+0.06  (0.22 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: DARA)  0.86  up arrow+0.01  (1.32 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NY: EMC)  24.96  down arrow-0.06  (-0.24 %)  Updated: 06:40 PM EDT, Aug 28 2015
(NQ: Extreme Networks)  2.80  up arrow+0.05  (1.82 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: Facebook)  91.01  up arrow+1.28  (1.43 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NY: GLAXOSMITHKLINE)  41.25  up arrow+0.04  (0.1 %)  Updated: 06:40 PM EDT, Aug 28 2015
(NQ: Google)  630.38  down arrow-7.23  (-1.13 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NY: IBM)  147.98  down arrow-0.56  (-0.38 %)  Updated: 06:40 PM EDT, Aug 28 2015
(NY: LH)  119.61  down arrow-0.21  (-0.18 %)  Updated: 06:40 PM EDT, Aug 28 2015
(OP: Lenovo Group)  17.21  up arrow+0.65  (3.93 %)  Updated: 05:20 PM EDT, Aug 28 2015
(NY: MRK)  55.37  up arrow+0.42  (0.76 %)  Updated: 06:40 PM EDT, Aug 28 2015
(NQ: Microsoft)  43.93  up arrow+0.03  (0.07 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: NetApp)  31.62  up arrow+0.23  (0.73 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NY: NOVARTIS AG)  98.35  down arrow-0.29  (-0.29 %)  Updated: 06:40 PM EDT, Aug 28 2015
(OP: Novozymes A/S)  43.69  down arrow-0.3  (-0.68 %)  Updated: 05:20 PM EDT, Aug 28 2015
(NY: Pfizer)  32.66  down arrow-0.6  (-1.8 %)  Updated: 06:40 PM EDT, Aug 28 2015
(NQ: Pozen)  8.85  up arrow+0.02  (0.23 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NY: Red Hat)  73.86  down arrow-0.34  (-0.46 %)  Updated: 06:40 PM EDT, Aug 28 2015
(NQ: BBRY)  7.37  up arrow+0.18  (2.5 %)  Updated: 08:10 PM EDT, Aug 28 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  11.05  up arrow+0.07  (0.64 %)  Updated: 08:10 PM EDT, Aug 28 2015

Posts tagged “GSK”

August 21

Novartis buying GSK multiple sclerosis drug for $1B plus royalties

GSK's HQ in London            GlaxoSmithKline has struck another major deal with Novartis. This time the drug giants are teaming up for a deal worth more than $1 billion plus royalties to GSK for an experimental multiple sclerosis drug. The deal will help GSK focus on other priorities, a top executive says.

August 17

Bezos disputes critical Amazon story; GSK plant reopens; Lenovo's new storage move; report links AT&T, NSA

Bulldog In today's Bulldog wrapup of technology and life science news: Jeff Bezos disputes a New York Times story critical of the company's work environment; GSK reopens its plant in Zebulon; Lenovo launches a new storage product; and a New York Times report links AT&T with the NSA.

August 17

GSK plans to reopen Zebulon plant Monday, says drugs are safe

GSK in Zebulon GlaxoSmithKline plans to reopen its Zebulon site Monday after bacteria that causes Legionnaires' disease was found in the cooling towers.

August 14

Pfizer-GSK rumors; Apple ups hiring of women, minorities; Dell's new Chromebooks; Pure Storage IPO; Tesla raising $500M

Bulldog In today's wrapup of technology and life science news: Rumors heat up that Pfizer wants GSK; Apple reports big increase in hiring of women and minorities; Dell's new Chromebooks; EMC, NetApp rival Pure Storage eyes IPO; and Tesla aims to raise $500 million.

August 13

GSK to resume production at Zebulon plant, says drugs are safe

GSK in Zebulon Pharmaceutical company GlaxoSmithKline (NYSE: GSK) anticipates resuming production at its Zebulon site in the next three days after bacteria that causes Legionnaires' disease was found in the cooling towers, a company spokesperson said Wednesday.

August 11

Premium Lock GSK drug spin-out Phoundry Phamraceuticals looking to raise $1M

Diabetes Phoundry Pharmaceuticals, a startup spun out from GlaxoSmithKline, has found eight investors and is looking for more as it aims to raise $1 million. The firm is targeting diabetes. It's also already backed by the N.C. Biotechnology Center.

August 10

Takeover talk sparks GSK shares; AT&T workers' contract expires; Tesla's cash burn; Buffet's bad quarter

Bulldog In today's Bulldog wrapup of technology and life science news: GlaxoSmithKline shares are climbing on takeover talk; AT&T workers in southeast are without a contract; Tesla is burning $4,000 in cash for very car sold; and a bad quarter for Warren Buffet's investments.

August 3

GSK rehires China exec; automakers buy Nokia map biz; Yahoo buys style-tip site; Zuckerbergs expecting; Windows 10 scam warning

Bulldog In today's wrapup of technology and life science news: GSK has rehired an executive linked to its China bribery scandal; German automakers are buying Nokia's map business in a step toward driverless cars; Yahoo buys a web startup; the Zuckerbergs are expecting; and a warning about a free Windows update scam.

July 29

Premium Lock Is GSK open to a merger? 'A big issue to cross,' CEO says

In a conference call, GlaxoSmithKline's top executive is asked if he would consider "pairing up" with another drug company. Back in May, an analyst started talk of a "PfizerKline" merger. GSK's CEO Andrew Witty notes a merger would be a "big issue to cross."

Andrew Witty      Andrew Witty

July 29

Premium Lock Ex-GSK employees facing layoffs at Parexel; firm won't comment

Layoffs        As many as 200 former GlaxoSmithKline employees who were transferred to life science services firm Parexel earlier this year are reportedly being laid off today. However, the Boston-based company which has a large presence in the Triangle, isn't talking.

July 29

Premium Lock GSK shares climb 3% after better-than-expected earnings

GSK's HQ in London            Shares in drug giant GlaxoSmithKline surged 3 percent early Wednesday after the company reported a better-than-expected decline in earnings. CEO Andrew Witty says the results are "encouraging."

July 22

Premium Lock Apple stock slides; Microsoft's $8.4B write-down; GSK suit; Yahoo's loss; Facebook loses warrant fight

Bulldog In today's Bulldog wrapup of technology and life science news: Apple stock tumbles as it stays coy on watch sales; Microsoft takes a huge write-down; GSK sues a software developer; Yahoo reports a quarterly bummer; and Facebook loses in warrant battle.

July 3

Premium Lock GSK's HIV drug deal with China; inside IBM's Wimbledon bunker; Red Hat adds SAP to cloud; Tesla sets record; Wi-Fi in Cuba

Bulldog In today's wrapup of technology and life science news: GSK makes an HIV drug deal with China; going inside IBM's bunker at Wimbledon; Red Hat adds SAP support to cloud services at Amazon; Tesla sets a record for car deliveries; and Cuba gets Wi-Fi hot spots.

July 2

Premium Lock Apple Watch forecast cut; robot kills worker; IBM's $1.5B chip deal closes; GSK vaccine, narcolepsy linked; AT&T-DirecTV deal nears OK

Bulldog In today's Bulldog wrapup of technology and life science news: An analyst says Apple Watch sales are slowing and he cuts forecast; a robot kills a worker in Germany; IBM closes on its $1.5 billion deal to dump its chip business; a GSK drug is linked to narcolepsy outbreak by study; and AT&T reportedly wins Justice Department OK for its DirecTV deal.

June 22

Premium Lock GSK sells 2 vaccines to Pfizer; Google 'revenge porn' crackdown; Tesla for the sky; Polish airline hack; eBay, Craigslist settle

Bulldog In today's Bulldog wrapup of tech and life science news: GSK is selling two meningitis vaccines to Pfizer; Google cracks down on "revenge porn;' a Tesla for the skies?; Polish airline is hacked; and eBay settles a dispute with Craigslist.

June 16

Premium Lock GSK funds 3 startups; Congress eyes data breach; HealthCare.gov risk; facial recognition debate; Triangle Cleantech update

Bulldog In today's Bulldog wrapup of technology and life science news: GlaxoSmithKline is funding three more startups at an incubator in San Diego; Congress looking into huge federal data breach; is HealthCare.gov data at risk?; facial recognition standards talks hit a roadblock; and an added position for the head of the Research Triangle Cleantech Cluster.

June 12

Premium Lock GSK's good news: FDA panel OKs asthma drug; cervical cancer vaccine in one dose

GSK   Drug giant GlaxoSmithKline received two doses of good news this week. An FDA committee on Thursday recommended its drug be approved for use in adults. Plus a new study says a cervical cancer vaccine appears effective with one dose.

May 20

Premium Lock 'Introducing PfizerKline'? Wall Street analysts sees Pfizer buying GSK

Pfizer  Where there is smoke is there fire when it comes to rumors that Pfizer might try to buy troubled GlaxoSmithKline? A Wall Street analyst is the latest to speculate that a mega merger could be in the works.

Updated May 11

Premium Lock GSK, UNC-Chapel Hill form company to seek HIV cure

Drug giant GlaxoSmithKline is teaming up with the University of North Carolina at Chapel Hill in an attempt to find a cure for AIDS. The two will form a new company called Qura Therapeutics and will launch an "HIV Cure Center" in Chapel Hill. GSK is committing $20 million over the next five years to fund the project.

May 7

Premium Lock New GSK board chair expresses support for CEO Witty

GSK's HQ in London            The new executive chair of GlaxoSmithKline came out in support of CEO Andrew Witty on Thursday, a day after Witty disclosed his strategy for bolstering the drug giant's future. "Andrew has the complete support of the board," said Philip Hampton. GSK also disclosed its new board lineup.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith